Beximco Pharmaceuticals enters EU market

Beximco Pharmaceuticals Limited (BPL), a Bangladesh-based manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has started to export its products to Europe with shipments of two ophthalmic products, Latanoprost and a combination of Latanoprost and Timolol.

These will initially be exported to Germany and Austria with other EU countries to follow.

Latanoprost and Timolol are used to reduce the pressure inside the eye for people with open-angle glaucoma or intraocular hypertension.

The company expects to launch additional products in the EU later this year.

Beximco’s Managing Director Nazmul Hassan said: ‘Beximco has established a presence in a growing number of markets around the world.

‘The company is increasingly focused on penetrating large and highly regulated markets such as the EU and US, where the demand for generic products continues to rise. Beximco has developed high quality pharmaceutical facilities in Bangladesh, with a competitive cost structure for manufacturing and exporting generic drugs.

‘This is a combination that is of increasing importance as governments strive to reduce healthcare costs without compromising on quality.

‘We look forward to launching further products in Europe, the second largest pharmaceutical market in the world with sales in excess of $265bn, and providing patients with safe and affordable treatment options.’

BPL, which operates from a 23-acre site in Dhaka, produces tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables and nebuliser solutions.

In addition to EU regulatory certification, BPL has also received accreditations from TGA Australia, GCC (Gulf member states), and ANVISA (Brazil).